Arb losartan
Pro Research Analysisby 
Searched over 200M research papers for "arb losartan"
The Therapeutic Potential of Losartan: A Comprehensive Review
Introduction to Losartan and Angiotensin II Receptor Blockers (ARBs)
Losartan is a widely used angiotensin II receptor blocker (ARB) that has been extensively studied for its therapeutic effects across various medical conditions. This article synthesizes the latest research on losartan, focusing on its efficacy in treating non-alcoholic steatohepatitis (NASH), bioprosthetic valve calcification, COVID-19, hyperuricemia, hypertension, pulmonary emphysema, type 2 diabetes, HIV-related inflammation, Alzheimer's disease, and heart failure.
Losartan in Non-Alcoholic Steatohepatitis (NASH)
A randomized controlled trial aimed to assess losartan's anti-fibrotic effects in patients with NASH. Despite the trial's early termination due to slow recruitment, preliminary results indicated that losartan might reduce fibrosis progression in NASH patients . However, further studies with larger sample sizes are needed to confirm these findings.
Losartan and Bioprosthetic Valve Calcification
Research using a rabbit model demonstrated that losartan significantly reduces calcification in bioprosthetic heart valves. The study found that losartan decreased calcium levels and suppressed the expression of inflammatory markers such as IL-6, osteopontin, and BMP-2, suggesting its potential in preventing structural valve deterioration .
Losartan in COVID-19 Treatment
A small prospective study investigated the impact of losartan on hospitalized COVID-19 patients with mild hypoxemia. The study concluded that adding losartan to standard care did not significantly affect clinical outcomes, such as the need for mechanical ventilation or mortality rates . Larger trials are necessary to explore any potential benefits further.
Losartan for Hyperuricemia and Gout
A review of multiple studies highlighted losartan's unique ability among ARBs to significantly reduce serum uric acid levels in patients with hyperuricemia or gout. This effect was not observed with other ARBs, making losartan a potentially valuable treatment option for managing hyperuricemia .
Losartan in Hypertension Management
The Kamanza Anti-Hypertensive Treatment Trial compared the efficacy of losartan/hydrochlorothiazide (Los/HCTZ) combination therapy to high-dose ARB monotherapy in patients with uncontrolled hypertension. Both treatments effectively reduced blood pressure without significant differences between the groups, suggesting that Los/HCTZ is a viable alternative to high-dose ARB therapy .
Losartan and Pulmonary Emphysema
A multicenter randomized trial evaluated losartan's efficacy in reducing emphysema progression in COPD patients. The study found no significant difference in emphysema progression between the losartan and placebo groups, indicating that losartan may not be effective in this context .
Losartan in Type 2 Diabetes and Nephropathy
A study on patients with type 2 diabetes and nephropathy showed that losartan improved glucose homeostasis and increased insulin sensitivity. These benefits were not observed with the calcium channel blocker amlodipine, highlighting losartan's potential in managing diabetes-related complications .
Losartan for HIV-Related Inflammation
A trial investigating losartan's effects on inflammation and fibrosis in HIV patients found no significant improvements in inflammatory markers or T-cell recovery. While losartan effectively reduced blood pressure, it did not provide additional benefits for inflammation-related comorbidities in this population .
Losartan and Alzheimer's Disease
Research on a mouse model of Alzheimer's disease suggested that losartan improves cognitive and cerebrovascular functions by blocking the angiotensin IV receptor (AT4R). These findings indicate that losartan may offer neuroprotective benefits independent of its blood pressure-lowering effects .
Losartan in Heart Failure Management
The HEAAL study compared high-dose (150 mg) and low-dose (50 mg) losartan in heart failure patients. The high-dose group experienced a lower rate of death or heart failure-related hospitalizations, demonstrating the importance of dose optimization in achieving clinical benefits .
Conclusion
Losartan exhibits a broad spectrum of therapeutic effects across various conditions, from reducing fibrosis in NASH to improving insulin sensitivity in diabetes. While some studies highlight its potential benefits, others indicate the need for further research to confirm its efficacy in different contexts. Overall, losartan remains a valuable ARB with diverse clinical applications.
Sources and full results
Most relevant research papers on this topic
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
Losartan treatment for 96 weeks failed to recruit sufficient patients to determine its anti-fibrotic effects in non-alcoholic steatohepatitis patients.
The angiotensin II type 1 receptor blocker losartan attenuates bioprosthetic valve leaflet calcification in a rabbit intravascular implant model.
Losartan significantly reduces postimplant degenerative calcification of bovine pericardial bioprosthesis in a rabbit intravascular implant model.
DOI
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
Losartan addition to standard care in COVID-19 patients with mild hypoxemia showed no significant clinical impact.
The effect of angiotensin II receptor blockers on hyperuricemia
Losartan is the only angiotensin II receptor blocker that consistently reduces serum uric acid levels in patients with hyperuricemia, making it a safe and effective treatment option.
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy, reducing urinary protein excretion.
DOI